» Articles » PMID: 11163196

Inhibition of Th1 Differentiation by IL-6 is Mediated by SOCS1

Overview
Journal Immunity
Publisher Cell Press
Date 2001 Feb 13
PMID 11163196
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin 6 (IL-6) is a cytokine produced by immune and nonimmune cells and exhibits functional pleiotropy and redundancy. IL-6 plays an important role in the differentiation of several cell types. Here, we describe a novel function of IL-6: the negative regulation of CD4+ Th1 cell differentiation. While IL-6-directed CD4+ Th2 differentiation is mediated by IL-4, inhibition of Th1 differentiation by IL-6 is independent of IL-4. IL-6 upregulates suppressor of cytokine signaling 1 (SOCS1) expression in activated CD4+ T cells, thereby interfering with signal transducer and activator of transcription 1 (STAT1) phosphorylation induced by interferon gamma (IFNgamma). Inhibition of IFNgamma receptor-mediated signals by IL-6 prevents autoregulation of IFNgamma gene expression by IFNgamma during CD4+ T cell activation, thereby preventing Th1 differentiation. Thus, IL-6 promotes CD4+ Th2 differentiation and inhibits Th1 differentiation by two independent molecular mechanisms.

Citing Articles

Overview of Cytomegalovirus Ocular Diseases: Retinitis, Corneal Endotheliitis, and Iridocyclitis.

Kobayashi R, Hashida N Viruses. 2024; 16(7).

PMID: 39066272 PMC: 11281654. DOI: 10.3390/v16071110.


and host interactions in the manifestation of tuberculosis.

Abbasnia S, Hashem Asnaashari A, Sharebiani H, Soleimanpour S, Mosavat A, Rezaee S J Clin Tuberc Other Mycobact Dis. 2024; 36:100458.

PMID: 38983441 PMC: 11231606. DOI: 10.1016/j.jctube.2024.100458.


SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity.

Bidgood G, Keating N, Doggett K, Nicholson S Front Immunol. 2024; 15:1419951.

PMID: 38947335 PMC: 11211259. DOI: 10.3389/fimmu.2024.1419951.


Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.

Maiorano B, Schinzari G, Carbone C, Piro G, Rossi E, Di Maio M Front Immunol. 2024; 15:1401214.

PMID: 38799450 PMC: 11116647. DOI: 10.3389/fimmu.2024.1401214.


Targeting MELK improves PD-1 blockade efficiency in cervical cancer via enhancing antitumor immunity.

Wang D, Zou F, Li Y, Hu J, Gao L Mol Ther Oncol. 2024; 32(1):200759.

PMID: 38596298 PMC: 10869760. DOI: 10.1016/j.omton.2024.200759.